docetaxel

You have access
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
JEAN-DAVID FUMET, JULIE VINCENT, LEILA BENGRINE, AUDREY HENNEQUIN, LAURA GRANCONATO, REMI PALMIER and FRANÇOIS GHIRINGHELLI

Anticancer Research July 2020, 40 (7) 4011-4015; DOI: https://doi.org/10.21873/anticanres.14395
You have access
Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer
KOSUKE TAKAHASHI, YOSHIAKI OSAKA, YOSHIHIRO OTA, TAKAFUMI WATANABE, KENICHI IWASAKI, SHINGO TACHIBANA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA

Anticancer Research May 2020, 40 (5) 2827-2832; DOI: https://doi.org/10.21873/anticanres.14256
You have access
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO

Anticancer Research January 2020, 40 (1) 335-339; DOI: https://doi.org/10.21873/anticanres.13957
You have access
ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer
ELINA KAIKKONEN, OTTO ETTALA, ILKKA NIKULAINEN, PEKKA TAIMEN, ILARI LEHTINEN, PETER J. BOSTRÖM, PIRKKO-LIISA KELLOKUMPU-LEHTINEN and JOHANNA SCHLEUTKER

Anticancer Research October 2019, 39 (10) 5353-5359; DOI: https://doi.org/10.21873/anticanres.13728
You have access
Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells
SO INAMURA, HIDEAKI ITO, MINEKATSU TAGA, KATSUKI TSUCHIYAMA, HITOMI HOSHINO, MOTOHIRO KOBAYASHI and OSAMU YOKOYAMA

Anticancer Research October 2019, 39 (10) 5417-5425; DOI: https://doi.org/10.21873/anticanres.13735
You have access
Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells
HIROKO TAKAGI, HIROMI II, SUSUMU KAGEYAMA, EIKI HANADA, KEIKO TANIGUCHI, TAKU YOSHIYA, TOKUHIRO CHANO, AKIHIRO KAWAUCHI and SUSUMU NAKATA

Anticancer Research September 2019, 39 (9) 4811-4816; DOI: https://doi.org/10.21873/anticanres.13666
You have access
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer
KENJI NAKANO, AKIRA SETO, TORU SASAKI, WATARU SHIMBASHI, HIROFUMI FUKUSHIMA, HIROYUKI YONEKAWA, HIROKI MITANI and SHUNJI TAKAHASHI

Anticancer Research August 2019, 39 (8) 4337-4342; DOI: https://doi.org/10.21873/anticanres.13601
You have access
Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model
ROMAN BASS, DOMENICA ROBERTO, DANIEL ZONGJIE WANG, FERNANDO PENA CANTU, REZA M. MOHAMADI, SHANA O. KELLEY, LAURENCE KLOTZ and VASUNDARA VENKATESWARAN

Anticancer Research January 2019, 39 (1) 113-118; DOI: https://doi.org/10.21873/anticanres.13086
You have access
Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer
CARSTEN NIEDER, ELLINOR HAUKLAND, BÅRD MANNSÅKER, ADAM PAWINSKI, ROSALBA YOBUTA and JAN NORUM

Anticancer Research January 2019, 39 (1) 335-340; DOI: https://doi.org/10.21873/anticanres.13116
You have access
Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells
KATRIN SAK, HELEN LUST, MARJU KASE, MARIKA SAAR and JANA JAAL

Anticancer Research November 2018, 38 (11) 6209-6215; DOI: https://doi.org/10.21873/anticanres.12975

Main menu

User menu

Search

docetaxel

Pages